Blocking Type I Interferon Production: A New Therapeutic Option to Reduce  the HIV-1-Induced Immune Activation by Ries, Moritz et al.
Hindawi Publishing Corporation
Clinical and Developmental Immunology
Volume 2012, Article ID 534929, 9 pages
doi:10.1155/2012/534929
Review Article
Blocking Type I Interferon Production: A New Therapeutic
Optionto Reduce the HIV-1-Induced ImmuneActivation
MoritzRies,Kathrin Pritschet,andBarbaraSchmidt
Institute of Clinical and Molecular Virology, German National Reference Centre for Retroviruses, Friedrich-Alexander-Universit¨ at
Erlangen-N¨ urnberg, Schlossgarten 4, 91054 Erlangen, Germany
Correspondence should be addressed to Barbara Schmidt, baschmid@viro.med.uni-erlangen.de
Received 1 September 2011; Accepted 7 October 2011
Academic Editor: Mirko Paiardini
Copyright © 2012 Moritz Ries et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Highly active antiretroviral therapy has dramatically improved the morbidity and mortality of HIV-1-infected individuals. A total
of25licenseddrugsprovidethebasisforanoptimizedvirus-suppressivetreatmentofnearlyeachsubject.Thepromisesofimmune
reconstitution and normal life expectancy, however, fall short for a number of patients, either through inadequate recovery of
CD4+ T-cell counts or the occurrence of non-AIDS deﬁning malignancies. In this respect, the prevalence of Epstein-Barr virus-
associated Hodgkin lymphoma and human papillomavirus-related anal neoplasia is rising in aging HIV-1-infected individuals
despite antiretroviral therapy. An important cause appears to be the HIV-1-induced chronic immune activation, propagated by
inappropriate release of proinﬂammatory cytokines and type I interferons. This immune dysregulation can be reduced in vitro by
inhibitors blocking the endosomal acidiﬁcation. Recent data suggest that this concept is also of relevance in vivo, which opens the
door for adjuvant immunomodulatory therapies in HIV-1 infection.
1. Old Problems Solved:New Arise
In the past 15 years, the antiretroviral therapy has consider-
ably advanced. Due to eﬀorts of basic and clinical sciences
and pharmaceutical companies, a total of 25 antiretroviral
drugs are available which target diﬀerent steps of the HIV-1
replication cycle, namely, entry, reverse transcription, inte-
gration, and processing of the gag-pol precursor [1]. This
variety of drugs allows to select the optimal antiretroviral
combination for nearly each HIV-1-infected individual [2],
promising an eﬃcient and long-term virus suppression with
reconstitution of the immune system and almost normal life
expectancy. With growing experience in antiretroviral treat-
ment, however, evidence also increases that not all HIV-1-in-
fected patients proﬁt or continue to proﬁt from the blessings
ofantiretroviraltherapy.Obviously,suppressionofviralload
below detection limit does not completely reduce inﬂamma-
tion. As a result, long-term antiretrovirally treated patients
stillhaveanincreasedrisk of deathdueto non-AIDScompli-
cations, which are typically associated with aging, for exam-
ple, cardiovascular disease, osteoporosis, and end-organ fail-
ure [3]. Most notably, the prevalence of non-AIDS-associa-
ted malignancies is increasing, for example, Epstein-Barr
virus-associated Hodgkin lymphoma and human papillo-
mavirus-associated anal neoplasia [4].
Do HIV-1-infected subjects now just live long enough to
experience their tumor? Or are these complications a result
of the persistent immune activation? If this is the case, we
need to think about adjunctive therapeutical approaches to
limit the level of immune activation. One of the most pro-
inﬂammatory messengers in the body is the type I interfer-
ons. Therefore, this review aims to link current models of
IFN-alpha induction and suppression in human and simian
models of lentiviral infections with the results of most recent
clinical studies. The readers are also referred to three excel-
lent reviews which summarize the ﬁndings about the HIV-1-
induced immunopathogenesis [5–7].
2.Beyond HIV
“Complete” inhibition of viral replication—measured by the
reduction of the viral load below detection limit—is
obviously not suﬃcient to reverse the HIV-1-induced2 Clinical and Developmental Immunology
immunological damage in all patients. One reason may be
that the peripheral viral load does not reliably reﬂect the
situation in the lymphatic tissue [8]. Another explanation is
that the HIV-1-associated chronic immune activation, which
has recently come into the focus of scientiﬁc interest, plays a
more important role than previously thought. Early studies
in HIV-1-infected patients showed that the progression to
AIDS was more strongly associated with levels of chronic im-
mune activation than with viral loads [9–13]. Not only in
humans, but also in the macaque model, it was shown that
immune activation played a crucial role in lentiviral patho-
genesis.Theinfectionwithsimianimmunodeﬁciencyviruses
(SIV) is usually apathogenic in the natural hosts like sooty
mangabeys or African green monkeys [14, 15], whereas the
infection of rhesus macaques with pathogenic SIV strains
resembles the progressive course of human HIV-1 infection
[16]. Pathogenic and apathogenic lentiviral infections are
characterized by comparable viral loads in acute and chronic
phases of the disease and a similar degree of CD4+ T cell de-
struction in cell culture [7]. In contrast, T-cell activation
and programmed cell death as well as the secretion of pro-
inﬂammatory cytokines are signiﬁcantly enhanced in patho-
genic infections, which progress with a decline in helper T
cells and the occurrence of opportunistic infections [7].
3. Trigger of ImmuneStimulation
An important stimulus for the chronic immune activation is
the massive destruction of CD4+ T cells in the gastrointesti-
nal tract, which has been observed in primary and chronic
HIV-1 and SIV infections [17–22]. The resulting breach of
the mucosal barrier supports the translocation of intestinal
bacteria, which induces the production of proinﬂammatory
cytokines, type I interferons and a systemic immune acti-
vation through the lipopolysaccharide (LPS) of gram-nega-
tive species, and other microbial constituents [23]. As an
indicator of microbial translocation, circulating LPS levels
are elevated in HIV-1-infected individuals [17, 23] and SIV-
infected rhesus macaques [24]. Increased LPS levels in the
plasma were correlated with chronic immune activation and
were only partially reduced after administration of antiretro-
viral therapy [23].
Anotherpotenttriggerofimmunestimulationisthetype
I interferons. In 1957, Alick Isaacs und Jean Lindenmann
discovered a soluble substance, termed “interferon”, which
interfered with the inﬂuenza virus infection in cell culture
[25]. Meanwhile, a whole family of interferons and inter-
feron-like molecules have been identiﬁed [26]. Amongst
them are the strongly antiviral, antiproliferative, and im-
munomodulatorytypeIinterferons,mostlycomprisingIFN-
alphaandIFN-beta.In1999,theplasmacytoiddendriticcells
(PDC) were identiﬁed as major producers of these interfer-
ons in the blood [27, 28]. Although accounting for only 0.2–
0.5% of peripheral blood mononuclear cells, PDC produce
up to 1000-fold more IFN-alpha than any other cell in the
body [29]. Armed with the endosomal Toll-like receptors
(TLR) 7 and 9, PDC detect single-stranded RNA and CpG-
like DNA molecules, respectively [30]. These cells drive
a potent Th1 polarisation upon stimulation with respective
bacterial and viral ligands, thus acting as “watchdogs” of the
immune system [31, 32]. It should be considered that other
cell types besides PDC also produce type I IFN, which may
be important in particular on a tissue or host basis.
4. The Endosomal Enigma
High-titered infectious and noninfectious HIV-1 [33–38]
and in particular HIV-1-infected cells [39, 40] induce a ro-
bust IFN-alpha production. The attachment of virions to
PDC is crucially dependent on binding of the viral envelope
protein gp120 to the CD4 receptor on PDC, supported by
the ﬁnding that the degree of IFN-alpha induction is correla-
ted with the aﬃnity of the virus to CD4 [41]. In addition, the
PDC-speciﬁc C-type lectin BDCA2 [42] and the mannose
receptor [43] were reported to be involved in the attachment
of HIV-1 to PDC. After binding, HIV-1 can interact with the
coreceptors and infect the PDC [44], which has been ob-
served for CCR5- and CXCR4-tropic viruses [38, 40, 45–47].
Productive infection can be enhanced by maturation of PDC
via CD40 ligand, which reduces their capacity to produce
type I interferons, or by neutralizing secreted interferons us-
ing respective antibodies [34, 44].
The induction of type I interferon production by HIV-1,
however, is independent of coreceptor usage and fusion with
the plasma membrane [33, 37, 40, 41]. Notably, the IFN-
alpha induction could be blocked by drugs which interfere
with the endosomal acidiﬁcation, for example, chloroquine,
baﬁlomycin, ammonium chloride, and chlorpromazine [33,
39, 40, 48]. Together with the colocalization of HIV-1 with
the early endosomal antigen 1 in PDC [49], these ﬁndings
suggest that virions are taken up into endosomal compart-
mentsofPDC.Akeyobservationwasthatvirionswhichwere
no longer able to package viral RNA were severely impaired
intheIFN-alphainduction,indicatingthatviralnucleicacids
are required for the activation of PDC [33]. This ﬁnding is
consistent with the IFN-alpha induction by guanosin- and
uridine-rich single-stranded RNA motifs derived from the
5  untranslated region of HIV-1, which have been reported
to interact with TLR7 and TLR8 [50]. Whether TLR9 also
plays a role in this process is still controversially discussed.
In this respect, we observed that the IFN-alpha induction
by HIV-1-infected cells was blocked by lower concentrations
of chloroquine than a synthetic TLR7 ligand [40]. When
TLR-speciﬁc inhibitory oligonucleotides were used in the
macaque model, a role for TLR9 in the induction of IFN-
alpha production by SIV could not be excluded [51]. In a
most recent study, however, TLR7 was silenced by siRNA
in a plasmacytoid cell line; thereby, the authors could show
thatthemajorityofIFN-alphaproductionbyHIV-1-infected
cellsisthroughTLR7[39].Moreover,when293Tcells,which
do not express endosomal TLRs, were transfected with CD4
and CXCR4 and subsequently exposed to HIV-1-infected
cells,anIFN-betapromoterwasinduced[39].Theseﬁndings
provide ﬁrst evidence that HIV-1 RNA may be recognized by
cytosolic pattern recognition receptors, which induces a type
I interferon production through interferon response factor
(IRF) 3.Clinical and Developmental Immunology 3
Altogether, the data support a model (Figure 1), in which
the IFN-alpha production is initiated by the endocytic up-
take of virions into PDC. Nucleic acids are released upon
endosomal acidiﬁcation and preferentially interact with
TLR7 to promote a signaling cascade via MyD88 and IRF7.
The relevance of the TLR-independent recognition of HIV-1
in PDC still has to be analyzed.
5. The Vicious Circle of Type 1 Interferons
The induction of type I interferons has beneﬁcial eﬀects, as
HIV-1-infected cells are driven into the programmed cell
death [6], and viral replication is reduced by 1(−2)log
[44, 52, 53]. However, the increased induction of IFN-alpha
production by infectious and noninfectious virions is also
detrimental, as addressed by several groups (reviewed in
[54]). In this respect, it was shown by the group of Gene
Shearer, NIH Bethesda, that the TNF-related apoptosis-in-
ducing ligand (TRAIL) and its death receptor (DR) 5 was
inducedonCD4+Tlymphocytesintheperipheralbloodand
in secondary lymphatic tissue [36, 37, 55]. This mechanism
leads to the apoptosis of uninfected CD4+ T cells, thereby
contributing to the characteristic destruction of the
lymph node architecture in advanced stages of HIV-1 infec-
tion. Moreover, the PDC-derived IFN-alpha induces the im-
munosuppressive enzyme indoleamine-2,3-dioxygenase
(IDO),whichleadstoreducedCD4+T-cellproliferationand
T-cell dysfunction [56, 57] and enhanced activity of T-regu-
latory cells [58]. Concomitantly with these ﬁndings, a sig-
nature of increased IFN-alpha production, namely, the up-
regulation of IFN-responsive genes, is observed in peripheral
cells and in the lymphatic tissue of HIV-1-infected indivi-
duals [36, 37, 55, 59, 60] .T h e s ed a t ah a v eb e e nc o n ﬁ r m e d
in primate lentiviral models, in which pathogenic SIV infec-
tions were associated with increased IFN-alpha and TRAIL
levels [51, 61]. Further corroboration comes from studies of
apathogenic SIV infections, in which the strong type I inter-
feron response in acute infections was quickly downregu-
lated,whereaspersistentIFN-alphaproductionwasobserved
during pathogenic SIV infection of rhesus macaques [62–
65].
Is the immune stimulation reﬂected by an elevated level
of circulating type I interferons in HIV-1-infected individu-
als? Older studies say so [66–68], but this has recently been
questioned when similar IFN-alpha levels were measured in
viremic and aviremic HIV-1-infected individuals and unin-
fected controls [69]. An explanation may be that elevated
IFN-alpha levels in the periphery are primarily present in
patients with end-stage disease. In countries with access to
highly active antiretroviral therapy, however, these individu-
als have become rare. Another important aspect is that HIV-
1-infected cells induce 10–100-fold more IFN-alpha com-
pared to cell-free virions, as shown by the use of transwell
chambers and gentle shaking of cocultures [39, 40]. These
ﬁndings are consistent with an increased transfer of viruses
by ﬁlopodial bridges [70]. Thus, the major release of IFN-
alpha—and consequently its detrimental eﬀects—appear to
occur preferentially in the lymphatic tissue, where HIV-1-
infected cells are in close contact with PDC, which enhances
cell-to-cell transfer of HIV-1 [71]. In a recent in vivo study,
PDC accumulated in the spleens of HIV-1-infected subjects
[72]. Interestingly, IFN-alpha did not colocalize with PDC
but other cells, for example, T and B cells, which may reﬂect
uptake of the cytokine via IFN-alpha receptors [72]. Another
important site is the mucosal tissue, to which PDC are
recruited in pathogenic SIV infection of rhesus macaques
[73].
The increased type I interferon production upon stim-
ulation with HIV-1-infected cells in the lymphatic tissue is
faced by a decreased IFN-alpha response of peripheral cells
to TLR stimulation. On the one hand, this is due to reduc-
ed PDC counts in HIV-1 infection, which has been conﬁrm-
ed by many groups (reviewed in [5]). On the other hand,
progressive disease comes along with functional PDC deﬁ-
cits, in particular, reduced IFN-alpha production upon sti-
mulation with TLR7 and TLR9 agonists [74–78]. In early
stages of HIV-1 infection (Fiebig V-VI), however, PDC re-
tain the ability to respond to TLR7/8 stimulation [79]. Not-
ably, numerical and functional PDC deﬁcits are not com-
pletely restored by antiretroviral therapy [80, 81]. The on-
going innate immune defect may account for the increase of
viral infections and associated tumors that are in principle
susceptible to type I interferons. In this respect, it is intrigu-
ing to look at the spectrum of opportunistic infections in the
immune reconstitution inﬂammatory syndrome, which oc-
curs in about 20% of HIV-1-infected individuals on newly
initiated antiretroviral therapy. Besides genital warts, there is
a high frequency of genital herpes, molluscum contagiosum,
andvaricella-zostervirus[82],whichareknownorsuspected
to be TLR9 agonists [83]. Similarly striking is the increase of
papillomavirus-associated anal neoplasia in HIV-1-infected
patients despite antiretroviral therapy; these lesions are
responsive to the TLR7 agonist imiquimod [4, 84].
How can the reduced responsiveness of PDC to TLR
stimulation in the periphery be put together with the en-
hanced IFN-alpha release particularly in the lymphatic tis-
sue?Tiltonandcolleaguesprovidedanappealingexplanation
saying that PDC were preactivated via type I IFNs or virions
in vivo, which prohibited de novo stimulation in vitro
[60]. This has been questioned by a recent study, which
showed prolonged and repeated IFN-alpha signaling in PDC
exposedtoHIV-1duetoaninabilityofendosomestomature
[49]. Another hypothesis may be that the HIV-1-induced
immunestimulationsomehowactivelysuppressestheinduc-
tion of IFN-alpha production. As a result, PDC are no long-
er able to fulﬁll their purpose as “watchdogs” of the immune
system: they now resemble “a dog that bites its tail.” A model
for the ambiguous role of type I interferons in the immuno-
pathogenesis of HIV-1 infection is proposed in Figure 2.
6. From Bench to Bedside
If one adopts the concept of chronic immune activation as a
major factor in the HIV-1 progression, the therapeutic con-
sequencewouldbetolimitthisimmunestimulation.Aproof
of principle was provided by early studies using low-dose
prednisolone, which signiﬁcantly stabilized CD4+ T-cell4 Clinical and Developmental Immunology
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Figure 1: Proposed model of the type I interferon induction by HIV-1 and HIV-1-infected cells. Attachment to the CD4 receptor of
plasmacytoid dendritic cells (PDC) triggers the HIV-1 uptake into an endosomal compartment. Subsequent acidiﬁcation releases nucleic
acids from lysed virions, preferentially recruits Toll-like receptor (TLR) 7, and activates the MyD88-dependent pathway. Translocation of
the interferon response factor (IRF) 7 into the nucleus activates production of type I interferons (IFN). HIV-1 can also infect PDC via
interaction with CD4 and the coreceptors. So far, it is unclear whether virions can escape from the endosomal compartment and initiate
productive infection. Another pathway of type I interferon production was recently described in the absence of endosomal TLRs, namely,
the recognition of HIV-1 RNA via cytosolic pattern recognition receptors (PRR) and IRF3 [39]. The role of this pathway for the IFN-alpha
induction in PDC needs to be further elucidated.
Table 1: Eﬀect of chloroquine on the HIV-1 and SIV-induced type I interferon production and/or subsequent immune activation in vitro
and in vivo.
Study Design Species Read-out
[33, 40] In vitro Human Reduced IFN-alpha production
[51] In vitro Rhesus Reduced IFN-alpha production
[89] In vitro Human
Reduced IFN-alpha production, reduced CD8+ T-cell
activation (CD38), block of negative modulators of the
T-cell response (IDO, PDL-1), reduced PDC activation
and maturation
[91] In vivo Human R e d u c e dC D 8 +c e l la c t i v a t i o n( C D 3 8 +H L A - D R + ) ,
reduced CD4+ and CD8+ T-cell proliferation (Ki-67)
[92] In vivo Human
Reduced CD4+ T-cell proliferation (Ki-67), reduced
activation of CD8+ T cells (CD38+ HLA-DR+) and
monocytes (CD69), reduced plasma LPS levels, reduced
proinﬂammatory cytokines (IL-6, TNF-alpha), increase
in CD4+ T-cell percentages
counts in otherwise untreated HIV-1-infected patients [85].
These data were corroborated in individuals on HAART,
although the eﬀect on the CD4+ T cells was smaller [86]. In
early studies by the group of Zagury, a total of 27 and 242
HIV-1-infected subjects were vaccinated against IFN-alpha-
2b in a phase I/II study and a double-blind placebo-con-
trolled phase II/III clinical trial, respectively [87, 88].
Although the immunogenicity of the vaccine was low, indi-
viduals who responded to vaccination had a lower rate of
disease progression.
Ad i ﬀerent approach was used in recent studies, which
focused on the eﬀect of chloroquine on the HIV-1-related
immune activation (summarized in Table 1). Chloroquine,
which interferes with the endosomal acidiﬁcation, is licens-Clinical and Developmental Immunology 5
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Figure 2: Vicious circle of type I interferon (IFN) induction in HIV-1 infection. The IFN-alpha induction is no longer balanced in HIV-1
infection. In the lymphatic tissue, plasmacytoid dendritic cells (PDC) are activated through direct cell-to-cell contact with HIV-1-infected
cells, which creates an interferon-rich environment, promotes the apoptosis of uninfected T cells, inhibits T-cell functions, and destroys the
lymph node architecture. In the periphery, reduced PDC counts and function result in an impaired innate immune response to bacterial
and viral stimuli. Decreased natural killer (NK) cell functions may enhance the susceptibility to opportunistic infections and virus-induced
tumor growth. The occurrence of pathogens in the periphery further causes PDC activation and depletion into lymphatic tissues.
ed for the prophylactic treatment of malaria. It is also wide-
ly used in the treatment of autoimmune disorders, for exam-
ple, the rheumatoid arthritis, to curb the chronic immune
activation. In cell culture, chloroquine inhibited the induc-
tion of IFN-alpha production by HIV-1 and HIV-1-infected
cells, as outlined above. Chloroquine also decreased CD8+
T-cell activation and blocked two negative regulators of the
T-cell response, IDO, and programmed death ligand 1 [89].
When mice were treated with chloroquine, the production of
proinﬂammatory cytokines upon stimulation with LPS was
reduced [90] .T h e s ed a t aw e r er e c e n t l ys u p p o r t e da n de x -
tended by two clinical trials with HIV-1-infected individuals.
In the ﬁrst study, chloroquine was administered to 13
HAART-na¨ ıvesubjectsfor2months[91].Thepatientsshow-
ed immunological improvement, as the frequency of CD38+
HLA-DR+ CD8+ T cells, the proliferation of T cells, and cir-
culating LPS levels were signiﬁcantly reduced. The most
recent study included a total of 20 HIV-1-infected subjects,
whosuﬀeredfrominadequatereconstitutionofCD4+Tcells
despite suppressive antiretroviral therapy [92]. These im-
munological nonresponders received chloroquine for six
months in addition to HAART, which was well tolerated ex-
cept for a skin rash in one case. Several immunological para-
meters improved as circulating LPS levels and activation of
CD4+ T cells and monocytes, and the production of inﬂam-
matory cytokines (IL-6, TNF-alpha) was reduced, docu-
menting the immunomodulatory eﬀect of adjuvant chloro-
quine treatment. Of note, the percentage (however not the
absolutecount)ofcirculatingCD4+TcellsandPDCincreas-
ed,suggestingthatsustainedreductionofimmuneactivation
translates into clinical response. These preliminary data,
however, should be interpreted with caution and need to be
reproduced in larger cohorts of HIV-1-infected individuals.
Such studies are in progress (ACTG A5258, http://clinical-
trials.gov/ct2/show/NCT00819390; CTN 246, http://www.
clinical-studies/canadian-hivtrials-database/ctn-246/).
7. Immune Modulation In Vivo
The endosome is an interesting target for immune modu-
lation, because drugs acting at this compartment are not
associated with broad immunosuppression, which is well
known for high-dose corticoid treatment. In this respect, it is
interesting that chloroquine was enriched in adenoid tissues,
thus being targeted to the center of the HIV-1-induced
immunopathogenesis [93]. It should be considered that
chloroquine may aggravate the peripheral unresponsiveness
of PDC to TLR stimulation, as the IFN-alpha induction by
CpG oligodeoxynucleotides and synthetic TLR7 agonists can
also be blocked by chloroquine. These ﬁndings may explain
why chloroquine administration in otherwise untreated
HIV-1-infected patients has not prevailed in the past 15
years. Thus, chloroquine appears to be promising only if
used in combination with suppressive antiretroviral therapy.
Long-term studies will show whether chloroquine will help
to restore PDC counts and function in the periphery, which
will hopefully also reduce the frequency of non-AIDS-asso-
ciated tumors. It also needs to be investigated whether6 Clinical and Developmental Immunology
chloroquine suﬃces to revert all signs of chronic immune
activation. It may well be possible that a few HIV-1-infected
patients will proﬁt from a more potent reduction of immune
activation. Potential candidates are biologicals used for the
treatment of autoimmune diseases, for example, IL-6 recep-
tor antagonists, antibodies against TNF-alpha, or soluble
TNF-alpha receptors.
8. Concluding Remarks
The concept of chronic immune activation in the immuno-
pathogenesis of HIV-1 infection has opened the door for ad-
juvant immunomodulatory therapies. Future will tell wheth-
er the antiretroviral therapy and quality of life of HIV-1-in-
fected individuals can further be improved. Continuous ef-
forts of basic and applied sciences and pharmaceutical com-
panies are required to stay on an upward track.
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